Skip to main content
Erschienen in: European Radiology 1/2013

01.01.2013 | Musculoskeletal

Radiographic features of multifocal endosteal thickening of the femur in patients on long-term bisphosphonate therapy

verfasst von: P. Chandra Mohan, Tet Sen Howe, Joyce S. B. Koh, Meng Ai Png

Erschienen in: European Radiology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To describe the characteristics of multifocal endosteal thickening in patients on bisphosphonate therapy.

Method

A retrospective study of 68 patients with atypical femoral fractures (as defined by ASBMR) whilst on bisphosphonate therapy was performed. Femoral radiographs were assessed for: focal endosteal thickening, number of lesions, lesion location, femoral bowing, periosteal beak and black line. Medical records were reviewed to obtain relevant clinical data.

Results

Forty-eight lesions with multifocal endosteal thickening were detected in seven patients (2 unilateral, 5 bilateral), affecting 11.8 % of femora. Location was mainly diaphyseal (95.8 %), upper (10.4 %), middle (58.3 %) and lower femur (31.3 %), involving the lateral (85.4 %), anterior (6.3 %), anterolateral (2.1 %) and posterior cortices (6.3 %). Femoral bowing was present in 85.7 %. Associated findings of a periosteal beak and/or a black line, seen in 14.6 %, were associated with increased fracture risk (100.0 % sensitivity, 93.2 % specificity).

Conclusions

Multifocal endosteal thickening is a new finding seen in patients with low bone mineral density on bisphosphonate therapy. They are rare, frequently bilateral, predominantly diaphyseal in location involving the lateral cortex and often associated with bowing. Caution is advised when seen in association with periosteal beak and/or black line because of a high rate of progression to complete fracture.

Key Points

Multifocal endosteal thickening in the femur is a newly described radiographic finding.
It is seen in patients with atypical femoral fractures whilst on bisphosphonate therapy.
It typically involves the lateral cortex in the lower femur.
A periosteal beak and/or black line may indicate an impending fracture.
Literatur
1.
Zurück zum Zitat Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294PubMedCrossRef Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294PubMedCrossRef
2.
Zurück zum Zitat Park-Wyllie LY, Mamdani MM, Juurlink DN et al (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783–789PubMedCrossRef Park-Wyllie LY, Mamdani MM, Juurlink DN et al (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783–789PubMedCrossRef
3.
Zurück zum Zitat Rogers LF, Taljanovic M (2010) FDA statement on relationship between bisphosphonate use and atypical subtrochanteric and femoral shaft fractures: a considered opinion. AJR Am J Roentgenol 195:563–566PubMedCrossRef Rogers LF, Taljanovic M (2010) FDA statement on relationship between bisphosphonate use and atypical subtrochanteric and femoral shaft fractures: a considered opinion. AJR Am J Roentgenol 195:563–566PubMedCrossRef
4.
Zurück zum Zitat Porrino JA, Kohl CA, Taljanovic M, Rogers LF (2010) Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy. AJR Am J Roentgenol 194:1061–1064PubMedCrossRef Porrino JA, Kohl CA, Taljanovic M, Rogers LF (2010) Diagnosis of proximal femoral insufficiency fractures in patients receiving bisphosphonate therapy. AJR Am J Roentgenol 194:1061–1064PubMedCrossRef
5.
Zurück zum Zitat Chan SS, Rosenberg ZS, Chan K, Capeci C (2010) Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. AJR Am J Roentgenol 194:1581–1586PubMedCrossRef Chan SS, Rosenberg ZS, Chan K, Capeci C (2010) Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. AJR Am J Roentgenol 194:1581–1586PubMedCrossRef
6.
Zurück zum Zitat Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224–231PubMedCrossRef Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224–231PubMedCrossRef
7.
Zurück zum Zitat Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349–353PubMedCrossRef Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349–353PubMedCrossRef
8.
Zurück zum Zitat Kwek EB, Koh JS, Howe TS (2008) More on atypical fractures of the femoral diaphysis. N Engl J Med 359:316–318PubMedCrossRef Kwek EB, Koh JS, Howe TS (2008) More on atypical fractures of the femoral diaphysis. N Engl J Med 359:316–318PubMedCrossRef
9.
Zurück zum Zitat Koh JS, Goh SK, Png MA, Kwek EB, Howe TS (2010) Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma 24:75–81PubMedCrossRef Koh JS, Goh SK, Png MA, Kwek EB, Howe TS (2010) Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? J Orthop Trauma 24:75–81PubMedCrossRef
10.
Zurück zum Zitat Koh JSB, Goh SK, Png MA et al (2011) Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. Singapore Med J 52:77–80PubMed Koh JSB, Goh SK, Png MA et al (2011) Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. Singapore Med J 52:77–80PubMed
11.
Zurück zum Zitat Png MA, Koh JS, Goh SK, Fook-Chong S, Howe TS (2012) Bisphosphonate-related femoral periosteal stress reactions: scoring system based on radiographic and MRI findings. AJR Am J Roentgenol 198:869–877PubMedCrossRef Png MA, Koh JS, Goh SK, Fook-Chong S, Howe TS (2012) Bisphosphonate-related femoral periosteal stress reactions: scoring system based on radiographic and MRI findings. AJR Am J Roentgenol 198:869–877PubMedCrossRef
12.
Zurück zum Zitat Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102PubMedCrossRef Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102PubMedCrossRef
13.
Zurück zum Zitat Abrahamsen B, Eiken P, Eastell R (2010) Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 95:5258–5265PubMedCrossRef Abrahamsen B, Eiken P, Eastell R (2010) Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 95:5258–5265PubMedCrossRef
14.
Zurück zum Zitat Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301PubMedCrossRef Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301PubMedCrossRef
15.
Zurück zum Zitat Seeger LL, Hewel KC, Yao L, Gold RH, Mirra JM, Chandnani VP, Eckardt JJ (1996) Ribbing disease (multiple diaphyseal sclerosis): imaging and differential diagnosis. Am J Roentgenol 167:689–694 Seeger LL, Hewel KC, Yao L, Gold RH, Mirra JM, Chandnani VP, Eckardt JJ (1996) Ribbing disease (multiple diaphyseal sclerosis): imaging and differential diagnosis. Am J Roentgenol 167:689–694
17.
Zurück zum Zitat Shimano MM, Volpon JB (2009) Biomechanics and structural adaptations of the rat femur after hindlimb suspension and treadmill running. Braz J Med Biol Res 42:330–338PubMedCrossRef Shimano MM, Volpon JB (2009) Biomechanics and structural adaptations of the rat femur after hindlimb suspension and treadmill running. Braz J Med Biol Res 42:330–338PubMedCrossRef
18.
Zurück zum Zitat Shellhart WC, Hardt AB, Moore RN, Erickson LC (1992) Effects of bisphosphonate treatment and mechanical loading on bone modeling in the rat tibia. Clin Orthop Relat Res 278:253–259PubMed Shellhart WC, Hardt AB, Moore RN, Erickson LC (1992) Effects of bisphosphonate treatment and mechanical loading on bone modeling in the rat tibia. Clin Orthop Relat Res 278:253–259PubMed
Metadaten
Titel
Radiographic features of multifocal endosteal thickening of the femur in patients on long-term bisphosphonate therapy
verfasst von
P. Chandra Mohan
Tet Sen Howe
Joyce S. B. Koh
Meng Ai Png
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
European Radiology / Ausgabe 1/2013
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-012-2587-y

Weitere Artikel der Ausgabe 1/2013

European Radiology 1/2013 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.